HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Neutral rating on Minerva Neurosciences (NASDAQ:NERV) and maintained an $11 price target.
February 27, 2024 | 5:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterated a Neutral rating on Minerva Neurosciences with an $11 price target.
The reiteration of a Neutral rating and maintenance of the $11 price target by HC Wainwright & Co. suggests that the analyst sees no immediate catalysts that would significantly change the stock's valuation in the short term. This could lead to a neutral impact on the stock's price as the market has likely already priced in the analyst's expectations.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90